8-KAccepted Nov 2, 9:28 AM ET
Supernus Pharmaceuticals, Inc.: merger completed and $650,000,000 credit agreement
Accepted (ET)
9:28 AM
Nov 2, 2026
Filed
Nov 2, 2026
Documents
16
Size
1.9 MB
Summary
Supernus Pharmaceuticals, Inc.: merger completed and $650,000,000 credit agreement
What happened
- On Nov 2, 2026, in connection with the Merger, the Combined Company and certain subsidiaries entered into a Credit Agreement providing a senior secured term loan facility in an aggregate principal amount of $650,000,000, all of which was borrowed on the Closing Date. At the Effective Time, each share of Supernus common stock outstanding (other than excluded shares) was converted into the right to receive 1.5401 shares of Indivior common stock. Outstanding Supernus restricted stock units and options were assumed and converted into Indivior-denominated awards on the terms described in the filing. The company’s certificate of incorporation and bylaws were amended and restated at the Effective Time.
Key details
- Credit Facility: $650,000,000 senior secured term loan, borrowed in full on Nov 2, 2026.
- Interest and prepayment: initial interest option of Term SOFR plus 2.25% or Base Rate plus 1.25% until the first quarterly statements are delivered; thereafter margins vary based on total net leverage ratio (Term SOFR plus 2.00% to 2.75% or Base Rate plus 1.00% to 1.75%). The Combined Company may prepay the facility, in whole or in part, without penalty subject to notice requirements.
- Guarantees and security: obligations guaranteed by certain subsidiaries in the United States, England and Wales, Scotland or Northern Ireland; secured by first priority liens on substantially all current and future tangible and intangible property and pledges of equity of certain subsidiaries, subject to customary exceptions.
- Merger equity treatment: exchange ratio of 1.5401 Indivior shares per Supernus share; Supernus RSUs and PSUs were converted to Indivior RSUs (PSUs converted to time-based awards) with rounding down rules; Supernus options were converted to Indivior options with adjusted exercise prices and rounding rules described in the filing.
Why it may matter
- The filing reports Item 1.01 (entry into a material definitive agreement) describing the Credit Agreement and its material terms; Item 2.01 (completion of acquisition) describing the Merger and conversion of Supernus equity; and Items 5.01 and 5.03 describing amendments and restatements of the certificate of incorporation and bylaws. This filing does not show why the insider traded or why the company acted.